Tue, 10 Jun 2008 14:58:12 -0400 PeerView Press http://www.peerviewpress.com Podcast Maker v1.3.3 - http://www.lemonzdream.com/podcastmaker PeerView Press is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerView Publications, PeerView Press is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes. Thought leader perspectives on current clinical advances in medicine PeerView Press is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerView Publications, PeerView Press is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes. en-us 2006 PeerView Press, 24 West 40th Street, Suite 950, New York, NY 10018 webmaster@peerviewpress.com http://podcast.peerviewpress.com/cardiology/cardiologyalbumart_144.jpg http://www.peerviewpress.com 144 144 Science & Medicine CME, Medical Education, continuing medical education, CME credits, PeerView Press, inSession, inReview, CE, Cardiology no PeerView Press In this CME activity, an expert in the management of hypertension and congestive heart failure discusses recent data on the vasodilatory beta-blockers in the treatment of both conditions. The differences between conventional and vasodilatory beta-blockers are also highlighted. Please be sure to view the accompanying (PDF) file for full CME/CE information. In this CME activity, an expert in the management of hypertension and congestive heart failure discusses recent data on the vasodilatory beta-blockers in the treatment of both conditions. The differences between conventional and vasodilatory beta-blockers are also highlighted. http://podcast.peerviewpress.com/cardiology/PA04119FCn179.mp3 http://podcast.peerviewpress.com/cardiology/PA04119FCn179.mp3 Fri, 25 Apr 2008 10:44:11 -0400 Science no 00:17:28 Beta-blockers, nebivolol, carvedilol, hypertension, CHF, heart failure, nitric oxide, vasodilation, CAPRICORN, SENIORS, blood pressure PeerView Press Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/cardiology/PA04119FCCMEinfo.pdf http://podcast.peerviewpress.com/cardiology/PA04119FCCMEinfo.pdf Fri, 25 Apr 2008 10:43:58 -0400 Science no 00:00:00 Beta-blockers, nebivolol, carvedilol, hypertension, CHF, heart failure, nitric oxide, vasodilation, CAPRICORN, SENIORS, blood pressure PeerView Press In this activity, experts in the management of acute coronary syndrome (ACS) describe the rationale and updated guidelines supporting the long-term use of dual antithrombotic therapy in patients who have undergone percutaneous coronary intervention (PCI) with stent placement. In addition, limitations regarding the pharmacokinetics of clopidogrel in this context lay the foundation for the discussion of novel antithrombotic agents in development. Please be sure to view the accompanying (PDF) file for full CME/CE information. In this activity, experts in the management of acute coronary syndrome (ACS) describe the rationale and updated guidelines supporting the long-term use of dual antithrombotic therapy in patients who have undergone percutaneous coronary intervention (PCI) with stent placement. In addition, limitations regarding the pharmacokinetics of clopidogrel in this context lay the foundation for the discussion of novel antithrombotic agents in development. http://podcast.peerviewpress.com/Pulmonology/PA04288FCr370.mp3 http://podcast.peerviewpress.com/cardiology/PA04288FCr370.mp3 Fri, 07 Mar 2008 14:55:55 -0500 Science no 00:34:05 Acute coronary syndrome, angioplasty, PCI, clopidogrel, aspirin, stent, paclitaxel-eluting, sirolimus-eluting, bare metal PeerView Press Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/cardiology/PA04288FCCMEinfo.pdf http://podcast.peerviewpress.com/cardiology/PA04288FCCMEinfo.pdf Fri, 07 Mar 2008 14:54:56 -0500 Science no 00:00:00 Acute coronary syndrome, angioplasty, PCI, clopidogrel, aspirin, stent, paclitaxel-eluting, sirolimus-eluting, bare metal PeerView Press In this interactive activity, an expert in the management of pulmonary arterial hypertension (PAH) presents three cases, by examining criteria that establish clinical status and the diagnosis of PAH. In addition, clinical-trial data are presented regarding the efficacy and safety of available and emerging therapies for this condition. Please be sure to view the accompanying (PDF) file for full CME/CE information. In this interactive activity, an expert in the management of pulmonary arterial hypertension (PAH) presents three cases, by examining criteria that establish clinical status and the diagnosis of PAH. In addition, clinical-trial data are presented regarding the efficacy and safety of available and emerging therapies for this condition. http://podcast.peerviewpress.com/Pulmonology/PA03751FCp115.mp3 http://podcast.peerviewpress.com/cardiology/PA03751FCp115.mp3 Wed, 15 Aug 2007 16:56:19 -0400 Science no 00:54:28 6-minute–walk distance, Ambrisentan, Bosentan, Cardiac catheterization,Echocardiography,endothelin-receptor antagonists,Epoprostenol,Hypertension, pulmonary arterial,Iloprost,Phosphodiesterase inhibitor,Prostacyclin,Raynaud’s phenomenon,Scleroderma PeerView Press Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/Pulmonology/PA03751FCCMEinfo.pdf http://podcast.peerviewpress.com/cardiology/PA03751FCCMEp115.pdf Wed, 15 Aug 2007 16:56:11 -0400 Science no 00:00:00 6-minute–walk distance, Ambrisentan, Bosentan, Cardiac catheterization,Echocardiography,endothelin-receptor antagonists,Epoprostenol,Hypertension, pulmonary arterial,Iloprost,Phosphodiesterase inhibitor,Prostacyclin,Raynaud’s phenomenon,Scleroderma PeerView Press In this activity, an expert will employ a case-based format to discuss strategies for assessing a patient’s risk for coronary heart disease (CHD) and optimally reducing the odds of CHD development in those with elevated risk. Please be sure to view the accompanying (PDF) file for full CME/CE information. In this activity, an expert will employ a case-based format to discuss strategies for assessing a patient’s risk for coronary heart disease (CHD) and optimally reducing the odds of CHD development in those with elevated risk. http://podcast.peerviewpress.com/cardiology/PA03593FCp116.mp3 http://podcast.peerviewpress.com/cardiology/PA03593FCp116.mp3 Fri, 01 Jun 2007 14:06:27 -0400 Science no 00:31:08 Type 2 diabetes mellitus, LDL-C, HDL-C, total cholesterol, triglycerides, non-HDL-C, hypertension, dyslipidemia, rosuvastatin, atorvastatin, simvastatin, pravastatin, fenofibrate, ezetimibe, niacin-ER, ATP III, NCEP, coronary heart disease, CHD, CVD, TLC PeerView Press Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/cardiology/PA03593FCCMEinfo.pdf http://podcast.peerviewpress.com/cardiology/PA03593FCCMEinfo.pdf Fri, 01 Jun 2007 14:05:58 -0400 Science no 00:00:00 Type 2 diabetes mellitus, LDL-C, HDL-C, total cholesterol, triglycerides, non-HDL-C, hypertension, dyslipidemia, rosuvastatin, atorvastatin, simvastatin, pravastatin, fenofibrate, ezetimibe, niacin-ER, ATP III, NCEP, coronary heart disease, CHD, CVD, TLC PeerView Press In this activity, expert cardiologists discuss the updated standard for prescribing antiplatelet therapy to avert subacute and long-term thrombotic complications associated with PCI and stent placement. In addition, the clinical development of pharmacologically distinctive antiplatelet agents is discussed. Please be sure to view the accompanying (PDF) file for full CME/CE information. In this activity, expert cardiologists discuss the updated standard for prescribing antiplatelet therapy to avert subacute and long-term thrombotic complications associated with PCI and stent placement. In addition, the clinical development of pharmacologically distinctive antiplatelet agents is discussed. http://podcast.peerviewpress.com/cardiology/PA03752FCr291.mp3 http://podcast.peerviewpress.com/cardiology/PA03752FCr291.mp3 Mon, 30 Apr 2007 16:07:47 -0400 Science no 00:28:11 Antiplatelet, Aspirin, AZD6140, Cangrelor, Clopidogrel, NSTEMI, Percutaneous coronary intervention (PCI), Platelet inhibition, Prasugrel, STEMI, Stent, Stent, bare-metal, Stent, drug-eluting, Thienopyridines, Thrombosis, coronary, Ticlopidine PeerView Press Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/cardiology/PA03752FCCMEinfo.pdf http://podcast.peerviewpress.com/cardiology/PA03752FCCMEinfo.pdf Mon, 30 Apr 2007 16:07:40 -0400 Science no 00:00:00 Antiplatelet, Aspirin, AZD6140, Cangrelor, Clopidogrel, NSTEMI, Percutaneous coronary intervention (PCI), Platelet inhibition, Prasugrel, STEMI, Stent, Stent, bare-metal, Stent, drug-eluting, Thienopyridines, Thrombosis, coronary, Ticlopidine PeerView Press In this activity, experts discuss current concepts in antithrombotic therapy in patients with acute coronary syndromes (ACS). Benefits and limitations of different antithrombotic agents and current recommendations for management of patients with ACS are reviewed, the latest data on efficacy and safety of novel antithrombotic agents are discussed, and clinical implications of these data are assessed. Based on data presented at the American College of Cardiology (ACC) Scientific Sessions, March 11-14, 2006, Atlanta, Georgia. This content is not a publication of, sanctioned by, or an official part of the ACC 2006. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView Press or any of its supporters. Please be sure to view the accompanying (PDF) file for full CME/CE information. In this activity, experts discuss current concepts in antithrombotic therapy in patients with acute coronary syndromes (ACS). Benefits and limitations of different antithrombotic agents and current recommendations for management of patients with ACS are reviewed, the latest data on efficacy and safety of novel antithrombotic agents are discussed, and clinical implications of these data are assessed. Based on data presented at the American College of Cardiology (ACC) Scientific Sessions, March 11-14, 2006, Atlanta, Georgia. This content is not a publication of, sanctioned by, or an official part of the ACC 2006. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView Press or any of its supporters. http://podcast.peerviewpress.com/cardiology/PA03037FCcdmar06a.mp3 1 Mon, 15 May 2006 12:00:00 -0400 Science no 00:26:59 Acute coronary syndromes, ACS, percutaneous coronary intervention, PCI, NSTEMI, antithrombotic therapy, antithrombin therapy, direct thrombin inhibitor, DTI, bivalirudin, heparin, UFH, LMWH, glycoprotein IIb/IIIa inhibitor, GPIIb/IIIa PeerView Press Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/cardiology/PA03037FCCMEInfo.pdf 2 Mon, 15 May 2006 12:00:00 -0400 Science no 00:00:00 Acute coronary syndromes, ACS, percutaneous coronary intervention, PCI, NSTEMI, antithrombotic therapy, antithrombin therapy, direct thrombin inhibitor, DTI, bivalirudin, heparin, UFH, LMWH, glycoprotein IIb/IIIa inhibitor, GPIIb/IIIa